Avastin, Herceptin Biosimilars Get OKs From FDA Advisory Committee

By Sam | August 4, 2017

An FDA advisory panel unanimously recommended that the agency approve two biosimilars for the cancer treatments Avastin (bevacizumab) and Herceptin (trastuzumab).
Source: Generic Line

Posted in Generic Line